# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants

> **NCT06673927** · PHASE1 · COMPLETED · sponsor: **Shanghai Haiyan Pharmaceutical Technology Co., Ltd.** · enrollment: 104 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** YZJ-1139
- **DRUG:** YZJ-1139
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06673927
- **Lead sponsor:** Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2018-11-21
- **Final completion:** 2019-03-08
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673927, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06673927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*